anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Postoperative Cognitive Dysfunction (POCD) has attracted increased attention, but its precise mechanism remains to be explored. This study aimed to figure out whether HDAC6 could regulate NLRP3-induced pyroptosis by modulating the functions of HSP70 and HSP90 in microglia to participate in postoperative cognitive dysfunction in aged mice.
METHODS: Animal models of postoperative cognitive dysfunction in aged mice were established by splenectomy under sevoflurane anesthesia. Morris water maze was used to examine the cognitive function and motor ability. Sixteen-months-old C57BL/6 male mice were randomly divided into six groups: control group (C group), sham surgery group (SA group), splenectomy group (S group), splenectomy + HDAC6 inhibitor ACY-1215 group (ACY group), splenectomy + HDAC6 inhibitor ACY-1215 + HSP70 inhibitor Apoptozole group (AP group), splenectomy + solvent control group (SC group). The serum and hippocampus of mice were taken after mice were executed. The protein levels of HDAC6, HSP90, HSP70, NLRP3, GSDMD-N, cleaved-Caspase-1 (P20), IL-1β were detected by western blotting. Serum IL-1β, IL-6 and S100β were measured using ELISA assay, and cell localization of HDAC6 was detected by immunofluorescence. In vitro experiments, BV2 cells were used to validate whether this mechanism worked in microglia. The protein levels of HDAC6, HSP90, HSP70, NLRP3, GSDMD-N, P20, IL-1β were detected by western blotting and the content of IL-1β in the supernatant was measured using ELISA assay. The degree of acetylation of HSP90, the interaction of HSP70, HSP90 and NLRP3 were analyzed by coimmunoprecipitation assay.
RESULTS: Splenectomy under sevoflurane anesthesia in aged mice could prolong the escape latency, reduce the number of crossing platforms, increase the expression of HDAC6 and activate the NLRP3 inflammasome to induce pyroptosis in hippocampus microglia. Using ACY-1215 could reduce the activation of NLRP3 inflammasome, the pyroptosis of microglia and the degree of spatial memory impairment. Apoptozole could inhibit the binding of HSP70 to NLRP3, reduce the degradation of NLRP3 and reverse the protective effect of HDAC6 inhibitors. The results acquired in vitro experiments closely resembled those in vivo, LPS stimulation led to the pyroptosis of BV2 microglia cells and the release of IL-1β due to the activation of the NLRP3 inflammasome, ACY-1215 showed the anti-inflammatory effect and Apoptozole exerted the opposite effect.
CONCLUSIONS: Our findings suggest that hippocampal HDAC6 promotes POCD by regulating NLRP3-induced microglia pyroptosis via HSP90/HSP70 in aged mice.
BACKGROUND: Cementless total knee arthroplasty (TKA) has increased in popularity to potentially improve survivorship. Radiostereometric studies demonstrate increased component migration during the first 3 to 6 months in cementless constructs, generating concern for increased postoperative pain during early osseointegration. The purpose of this study was to evaluate short-term (≤ 6 months) pain and function in cemented versus cementless TKA. We hypothesized that cementless TKA patients report increased pain during the short-term (≤ 6 months) postoperative period.
METHODS: The MEDLINE, EMBASE, CINAHL, and Cochrane Libraries were searched for studies evaluating short-term (≤ 6 months) outcomes of cemented versus cementless primary TKA. Studies involving hybrid fixation were excluded. A meta-analysis was performed using standardized mean difference for primary outcomes (early postoperative pain) and weighted mean difference (WMD) for secondary outcomes (early postoperative function).
RESULTS: There were eleven studies included. There was no significant difference in acute postoperative pain between cemented and cementless TKA within 6 months of index TKA (standardized mean difference 0.08 in favor of cemented TKA; P = .10). Early postoperative forgotten joint scores (WMD 0.81; P = .81) and knee injury and osteoarthritis outcome scores for joint replacement (WMD 0.80 in favor of cemented TKA; P = .14) were also similar between groups.
CONCLUSIONS: There is no difference in short-term (≤ 6 months) pain or early function between patients receiving cemented and cementless TKA. This suggests that surgeons may utilize cementless TKA without fear of increased pain due to micromotion within 6 months of index arthroplasty. However, additional studies with uniform assessment methods are needed to further inform differences in short-term pain and early functional outcomes between cemented and cementless TKA.
Bioresorbable scaffolds are transient implants. They act like drug-eluting metallic stents (DES) during the first 3 months by supporting the vessel wall thereby keeping the artery patent. Subsequently, resorption of the scaffold begins and its structure loosens. As a result of everolimus release, neointimal growth is inhibited similar to DES. Finally the implant is reabsorbed completely in about 2-3 years. BVS in terms of late stent thrombosis may be safer than DES. Transiently scaffolded vessels may regain their natural curvature and angulation as well as response to nitroglycerine and endothelial function.
Residents of malaria-endemic regions are frequently exposed to a variety of other parasites concurrently with malarial parasites. In Mali, lymphatic filariasis co-exists in several regions highly endemic for malaria. Because of the chronicity of filarial infections and an associated bias towards the development of an adaptive immune response dominated by Th2 cytokines, a pre-existing filarial infection has the potential to alter the immune response towards incoming malarial parasites, clearance of which are considered to be dependent on a robust Th1 response. Conversely, immune responses to filarial parasites may be modulated in the presence of malarial parasites. The goal of this study is to determine the effect of concurrent infections with malarial and filarial parasites on innate and adaptive immune responses to homologous and heterologous antigens. We will characterize the responses of peripheral blood mononuclear cells to antigens derived from both filarial (Wuchereria bancrofti) and malarial (Plasmodium falciparum) parasites in groups of individuals with or without filarial infections and follow them through a malaria transmission season, when they are repeatedly exposed to malarial parasites, to determine how co-infection with the filarial parasite affects the cellular and humoral responses to malarial and filarial antigens. These studies may provide the basis for modifying treatment strategies of mass treatment of malaria in regions co-endemic for lymphatic filariasis.
Anthocyanins are extracted from blackcurrants, bilberries, elderberries and/or cherries by pressing and depectinising the fruit(s), separating the juice obtained from the solid residues, macerating the solid residues at least once in water, methanol, ethanol and/or butanol for from 4 to 24 hours, separating the residues and the liquid, adding the liquid to the juice and recovering the anthocyanins from the mixture of liquid and juice by filtering the mixture and then concentrating the filtered liquid. The liquid and juice may be pre-concentrated under a partial vacuum and pre-concentrated material so obtained may be completely dried under vacuum in the presence of an absorbent inert powder such as cellulose, talc, kaolin, kieselguhr, silica and/or calcium phosphate. The macerating solvent(s) may be acidified and the solvent vapours may be recovered and recycled. The pre-concentrated liquid and juice may be purified by means of ion exchange resins, chromatography or by the foramtion of a neutralized aluminium oxide-anthocyanins complex which is then eluted in an acid medium. Pharmaceutical compositions having effects on capillary permeability and resistance and on circulatory dynamics and vitamin P activity comprise the extracted anthocyanins and a carrier. The compositions may be administered orally, parenterally, topically or rectally in conventional pharmaceutical forms.
The invention relates to a traditional Chinese medicine tablet for improving sleep. Active components of the traditional Chinese medicine tablet include the following bulk drugs in terms of weight ratio: 15-20 of silktree albizzia bark, 20-25 of platycladi seed, 10-15 of polygala root, 10-15 of dragon bone, 15-20 of oyster, 20-25 of lily, 15-20 of date, 15-20 of vine of multiflower knotweed, 15-20 of tuber fleeceflower stem, 5-10 of radix scrophulariae, 10-20 of red-rooted salvia root, 5-10 of rhizoma gastrodiae, 10-15 of peanut and 1-3 of cinnabar. Water with a weight which is 5-8 times that of the total bulk drugs is added in the bulk drugs for reflux extraction performed by a hot-reflux low-temperature extraction densifier. Extracted medicine liquid undergoes filtration, concentration and spray drying. Then, xylitol with an appropriate amount is added in the extracted medicine liquid. After the procedures of pelletization, drying and tabletting, the tablet weighing 0.8 g is obtained. The traditional Chinese medicine tablet has the healthcare function of improving the sleep. Each time, 1-2 tablets are taken one hour before the sleep. The traditional Chinese medicine tablet is suitable for insomnia and dyssomnia sufferers.
The invention concerns a simplified process for the production of fluoride-containing, swellable magnesium layer silicates of the smectite type, in particular compounds of this type with the hectorite structure, the process including a hydrothermal reaction step between the layer-silicate-forming reactants at elevated pressures and temperatures. The new process is characterized in that a hydroxidic coprecipitate of magnesium and silicon, optionally virtually free of foreign salts, in alkaline aqueous suspension, and in the presence of dissolved MgSiF6 and/or other salts supplying fluoride ions, is subjected to a hydrothermal reaction and the solid formed is optionally separated, after cooling, from the aqueous phase and from any foreign salts dissolved in it. The moist product thus obtained does not swell significantly in water. The invention calls, as the last process step, for this moist product to be dried at moderately temperatures, thus forming in this step the crystalline, high-swelling layer silicate. The invention also concerns the use of layer silicates produced in this way in the thickening of liquid aqueous phases. When layer silicates produced by the process proposed are provided, using prior art methods, with oleophilic groups, these modified thickening agents are suitable for use in organic phases.
INTRODUCTION: The agreement between the radiologic and histopathologic tumor locations in T2 gallbladder cancer is critical. There is no consensus regarding the extent of curative resection by tumor locations.
METHODS: Between January 2010 and December 2019, a consecutive series of 118 patients with pathological T2 gallbladder cancer who underwent surgery were retrospectively analyzed in terms of the accordance between radiologic and histopathologic tumor locations, the extents of hepatic resection and the numbers of harvested lymph nodes. Radical resection was defined as liver resection with harvesting of at least four lymph nodes.
RESULTS: The accuracy of preoperative tumor localization was only 68%. After radical resection, the 5-year overall survival (OS) was 59.4%; after nonradical resection, the figure was 46.1% (p = 0.092). In subanalyses, the 5-year OS was marginally better for patients who underwent liver resection or from whom at least four lymph nodes were harvested than those who did not undergo liver resection or from whom three or fewer lymph nodes were harvested (58.2% vs. 39.4%, p = 0.072; 59.9% vs. 50.0%, p = 0.072, respectively). In patients with peritoneal side tumor, the 5-year OSs of those who did and did not undergo liver resection were 67% and 41.2%, respectively (p = 0.028). In multivariate analysis, perineural invasion and radical resection were independently prognostic of OS.
CONCLUSION: The accuracy of preoperative tumor localization was 68%. Hepatic resection, lymph node dissection harvesting of at least four lymph nodes are required for curative resection for gallbladder cancer, regardless of tumor location.
In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
The proposed project will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks into a virtual environment and is synchronized with cycling to promote cognition. Cycling through an interesting virtual environment will motivate and engage the older adult to participate in the exercise, and VRCT could augment cycling's effects on cognition. The purpose of this project is to demonstrate the feasibility and efficacy of the exergame intervention on cognition through two phases. In Phase I, a prototype of the VRCT exergame will be developed, followed by a feasibility testing using a single-group mixed methods design. In Phase II a more fully-featured version of the VRCT exergame will be developed followed by a an RCT which will randomize subjects on a 2:1:1 allocation ratio to 3 parallel groups (exergame:cycling only:attention control). Mixed methods will be used to assess outcomes in both phases.
Lipid dysregulations have been critically implicated in Alzheimer's disease (AD) pathology. Chemical analysis of amyloid-β (Aβ) plaque pathology in transgenic AD mouse models has demonstrated alterations in the microenvironment in the direct proximity of Aβ plaque pathology. In mouse studies, differences in lipid patterns linked to structural polymorphism among Aβ pathology, such as diffuse, immature, and mature fibrillary aggregates, have also been reported. To date, no comprehensive analysis of neuronal lipid microenvironment changes in human AD tissue has been performed. Here, for the first time, we leverage matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) through a high-speed and spatial resolution commercial time-of-light instrument, as well as a high-mass-resolution in-house-developed orbitrap system to characterize the lipid microenvironment in postmortem human brain tissue from AD patients carrying Presenilin 1 mutations (PSEN1) that lead to familial forms of AD (fAD). Interrogation of the spatially resolved MSI data on a single Aβ plaque allowed us to verify nearly 40 sphingolipid and phospholipid species from diverse subclasses being enriched and depleted, in relation to the Aβ deposits. This included monosialo-gangliosides (GM), ceramide monohexosides (HexCer), ceramide-1-phosphates (CerP), ceramide phosphoethanolamine conjugates (PE-Cer), sulfatides (ST), as well as phosphatidylinositols (PI), phosphatidylethanolamines (PE), and phosphatidic acid (PA) species (including Lyso-forms). Indeed, many of the sphingolipid species overlap with the species previously seen in transgenic AD mouse models. Interestingly, in comparison to the animal studies, we observed an increased level of localization of PE and PI species containing arachidonic acid (AA). These findings are highly relevant, demonstrating for the first time Aβ plaque pathology-related alteration in the lipid microenvironment in humans. They provide a basis for the development of potential lipid biomarkers for AD characterization and insight into human-specific molecular pathway alterations.
PURPOSE:The titled kneaded liquid, containing aluminum phosphate, sodium chloride and a surfactant, and capable of increasing the strength and fire resistance at high temperatures and improving the surface conditions of a cast material. CONSTITUTION:A kneading liquid of a dental investment material, containing 0.6-6wt% aluminum phosphate, e.g. aluminum primary or secondary phosphate, 0.6-3wt% sodium chloride and 10-100ppm surfactant, e.g. nonionic or anionic surfactant, and having >=1.6pH. The mixing liquid ratio of the kneading liquid to be added to an investment material powder is suitably within 1:(0.2-0.4) range. The mixing of a gypsum based investment material by using the above-mentioned kneading liquid permits the casting of nickel-chromium alloy requiring >=1,300 deg.C temperature, and a prosthesis can be manufactured from the above- mentioned alloy.
An increasing number of studies have shown that Nonalcoholic fatty liver disease (NAFLD) is strongly associated with obesity, insulin resistance, dyslipidemia, hypertension and metabolic syndrome, but its specific pathogenesis remains unclear. By analyzing GEO database, we found CXCL6 was upregulated in liver tissues of patients with NAFLD. We also confirmed with qPCR that CXCL6 is highly expressed in serum of patients with NAFLD. To identify the underlying impact of CXCL6 on NAFLD, we established animal and cell models of NAFLD. Similarly, we confirmed by qPCR and Western blot that CXCL6 was upregulated in the NAFLD model in vitro and vivo. After transfecting NAFLD cells with siRNA targeting CXCL6 (si-CXCL6), a series of functional experiments were carried out, and these data indicated that the inhibition of CXCL6 reduced intracellular lipid deposition, decreased AST, ALT and TG level, facilitate cell proliferation and suppress their apoptosis. Furthermore, western blot and qPCR analyses displayed that the suppression of CXCL6 could raise the PPARα expression, but PPAR α inhibitor, GW6471 could partially counteract this effect. What's more, Oil Red O staining, biochemical analyzer and TG detection kit revealed that GW6471 could reverse the inhibitory effect of si-CXCL6 on NAFLD. In summary, we provide convincing evidence that CXCL6 is markedly elevated in NAFLD, and the CXCL6/PPARα regulatory network mediates disease progression of NAFLD.
Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 10 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
Pregnant women and adolescents (n=24) will be recruited when entering prenatal care. They will be invited to participate in a longitudinal study comparing the relative contribution of the two major maternal iron sources, i.e. maternal dietary iron intake and maternal red blood cell iron recycling, to fetal iron accretion during pregnancy. At about 15 weeks of gestation, participants will consume an oral dose of a stable iron isotope (57Fe as ferrous sulfate) to enrich their red blood cells (RBCs) with 57Fe. Maternal blood samples will be collected at 4 times during pregnancy to monitor changes in blood 57Fe concentrations. In the third trimester of pregnancy, women will consume a dose of a different iron isotope (58Fe as ferrous sulfate) as dietary nonheme iron. Cord blood samples and placental tissue will be obtained at delivery to determine how much of the dietary iron (58Fe) and RBC iron (57Fe) was transferred to the fetus and how much of each isotope was retained in the placenta. Placenta tissue samples will also be used to assess placental expression of iron transporters in relation to the amount of each iron isotopes transferred to the fetus. Circulating iron status indicators and regulators will be measured in all maternal and cord blood samples to examine the effect of iron status on placental transfer of iron derived from the diet vs. RBC during pregnancy.
<P>PROBLEM TO BE SOLVED: To fully automate combination authentication for determining whether a combination is appropriate.  <P>SOLUTION: An authentication apparatus includes an identification information automatic acquisition unit 3, a combination ID tag detection unit 4, and a combination confirmation unit 5. The identification information automatic acquisition unit 3, from an ID tag 2 located in a predetermined monitoring area Z, automatically acquires identification information held by the ID tag 2 through communication. The combination ID tag detection unit 4 monitors whether the ID tags 2 (2a, 2b) have approached in a predetermined state in the monitoring area Z. If the combination ID tag detection unit 4 has detected the approached ID tags 2a, 2b, the combination confirmation unit 5 determines whether the combination of the approached ID tags 2a, 2b is appropriate on the basis of automatically acquired identification information.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
The group of inventions relates to the pharmacy, in particular to the liquid pharmaceutical composition comprising GABA analogue and several polyols with 2-6 carbon atoms. The polyols make up 25-75% (m/v) of composition. pH of the composition is within 5.5-7.0 range. The formulation and the method for manufacturing such a composition are provided. The composition comprises the first component containing GABA analogue in a powder and the solid polyol and the second component providing for a liquid base. The composition may be used for treating the psychiatric disorders and brain injuries including epilepsy, hypokinesia, syncopes, neurodegenerative disorders, manias, and bipolar disorders. The composition may be used also for treating the inflammation, the renal colic, the insomnia, the gastrointestinal disorders, the pain including neuropathy pain, muscular pain and bone pain.